JP2022521208A - うつ病及び他の障害の治療のための組成物及び方法 - Google Patents

うつ病及び他の障害の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2022521208A
JP2022521208A JP2021548233A JP2021548233A JP2022521208A JP 2022521208 A JP2022521208 A JP 2022521208A JP 2021548233 A JP2021548233 A JP 2021548233A JP 2021548233 A JP2021548233 A JP 2021548233A JP 2022521208 A JP2022521208 A JP 2022521208A
Authority
JP
Japan
Prior art keywords
nri
maoi
hours
phenelzine
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521208A5 (enExample
Inventor
マギッド アブラハム
ケン ギルマン
Original Assignee
ニューラウェル セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューラウェル セラピューティクス filed Critical ニューラウェル セラピューティクス
Publication of JP2022521208A publication Critical patent/JP2022521208A/ja
Publication of JP2022521208A5 publication Critical patent/JP2022521208A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2021548233A 2019-02-17 2020-02-18 うつ病及び他の障害の治療のための組成物及び方法 Pending JP2022521208A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806831P 2019-02-17 2019-02-17
US62/806,831 2019-02-17
PCT/US2020/018567 WO2020168337A1 (en) 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders

Publications (2)

Publication Number Publication Date
JP2022521208A true JP2022521208A (ja) 2022-04-06
JP2022521208A5 JP2022521208A5 (enExample) 2023-03-01

Family

ID=72045151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548233A Pending JP2022521208A (ja) 2019-02-17 2020-02-18 うつ病及び他の障害の治療のための組成物及び方法

Country Status (7)

Country Link
US (1) US12465611B2 (enExample)
EP (1) EP3923919A4 (enExample)
JP (1) JP2022521208A (enExample)
CN (1) CN113631157A (enExample)
AU (2) AU2020223284A1 (enExample)
CA (1) CA3130580A1 (enExample)
WO (1) WO2020168337A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324976A (en) * 2023-06-16 2026-01-01 Neurawell Therapeutics Combination treatments for depression and other disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999382A (en) 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1715843A1 (en) 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
EP1737473A4 (en) 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
EP1879574A2 (en) 2005-02-23 2008-01-23 Prexa Pharmaceuticals, Inc. Multimediator 5-ht6 receptor antagonists, and uses related thereto
CN101163477A (zh) 2005-02-23 2008-04-16 普雷萨药品公司 多介质多巴胺转运抑制剂，以及其相关应用
CN102343084A (zh) 2005-03-31 2012-02-08 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
CA2604915A1 (en) 2005-04-22 2006-11-02 Wyeth New therapeutic combinations for the treatment or prevention of depression
WO2006116165A1 (en) 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
EP1998773A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware New therapeutic combinations for the treatment of depression
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
ES2500053T3 (es) * 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
JP2010526820A (ja) * 2007-05-07 2010-08-05 チェルシー・セラピューティクス，インコーポレイテッド 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
ES2689520T3 (es) 2010-04-23 2018-11-14 Kempharm, Inc. Formulación terapéutica para reducir los efectos secundarios de fármacos
WO2012048243A2 (en) 2010-10-08 2012-04-12 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
US20130217673A1 (en) * 2012-02-22 2013-08-22 Warsaw Orthopedic, Inc Mixed monoamine reuptake inhibitor in a biodegradable polymer carrier
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2014120936A2 (en) 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
US10624939B2 (en) 2017-05-23 2020-04-21 Luke Klele Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CN111233737B (zh) 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF NEURAL TRANSMISSION, vol. 125, JPN6024004899, 2018, pages 1707 - 1717, ISSN: 0005405353 *
PHARMACOTHERAPY, vol. 35, no. 4, JPN6024004900, 2015, pages 433 - 449, ISSN: 0005405354 *

Also Published As

Publication number Publication date
US12465611B2 (en) 2025-11-11
AU2023226657A1 (en) 2023-09-21
EP3923919A4 (en) 2022-12-07
US20220117975A1 (en) 2022-04-21
CN113631157A (zh) 2021-11-09
WO2020168337A1 (en) 2020-08-20
EP3923919A1 (en) 2021-12-22
WO2020168337A4 (en) 2020-10-08
AU2020223284A1 (en) 2021-09-16
CA3130580A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
Cheer et al. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness
TW202308601A (zh) 抑制5-ht2b激動劑形成之調配物及使用其之方法
CN113413387A (zh) 治疗炎症或神经性疼痛的方法
US10322121B2 (en) Methods of providing weight loss therapy in patients with major depression
WO2018206924A1 (en) Methods of treating doose syndrome using fenfluramine
AU2017202793B2 (en) Methods for Reducing Binge or Compulsive Eating
TWI428130B (zh) 治療急性躁狂症之藥學組成物及方法
TW202313003A (zh) 用於治療憂鬱之組成物及方法
WO2025128594A1 (en) Methods of treating generalized anxiety disorder
US20250268884A1 (en) Deuterated Domperidone for Treating Gastroparesis
JP2009515952A (ja) 制御放出性製剤のクエチアピン
Ciccone Geriatric pharmacology
AU2023226657A1 (en) Compositions and methods for treatment of depression and other disorders
Gentile Pregnancy exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions
JP2024540104A (ja) アルツハイマー病に関連する激越を治療する方法
TW200916091A (en) Neramexane for the treatment of nystagmus
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson&#39;s disease, or parkinson&#39;s disease motor disability using befiradol
WO2026085331A1 (en) Mefluleucin for use in the treatment of suicidal ideations associated with depression
HK40061449A (en) Methods of treating inflammation or neuropathic pain
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
RU2788450C2 (ru) Способы проведения терапии потери веса у пациентов с доминирующей депрессией
EFFEXOR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFEXOR XR safely and effectively. See full prescribing information for
Krasuski Dr. Jack’s MedQuik Guide
HK1188148B (en) Methods for reducing binge or compulsive eating
HK1188148A (en) Methods for reducing binge or compulsive eating

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240902